Announcement • Feb 17
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time. Announcement • Feb 07
Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026 Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026. Announcement • Feb 05
Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026 Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division. Announcement • Jan 28
Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026 Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026 Announcement • Jan 16
Sartorius Expands Bio-Circular Product Offering for More Sustainable Bioprocesses Sartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network. Announcement • Oct 17
Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025 Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%. Announcement • Apr 17
Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025 Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively. Announcement • Mar 29
Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025 Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025. Announcement • Feb 18
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025. Announcement • Feb 09
Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025 The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025. Announcement • Nov 16
Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025 Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025 Buy Or Sell Opportunity • Oct 25
Now 21% undervalued Over the last 90 days, the stock has risen 1.2% to €245. The fair value is estimated to be €309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.5% per annum. Earnings are also forecast to grow by 37% per annum over the same time period. Reported Earnings • Oct 18
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: €0.21. Revenue: €793.6m (down 2.1% from 3Q 2023). Net income: €14.2m (up 65% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 56%. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Announcement • Sep 19
Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3). Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin.
Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Buy Or Sell Opportunity • Aug 02
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 12% to €249. The fair value is estimated to be €316, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings are also forecast to grow by 34% per annum over the same time period. Price Target Changed • Jul 24
Price target decreased by 7.0% to €287 Down from €309, the current price target is an average from 16 analysts. New target price is 30% above last closing price of €221. Stock is down 38% over the past year. The company is forecast to post earnings per share of €2.22 for next year compared to €3.00 last year. Reported Earnings • Jul 19
Second quarter 2024 earnings: Revenues exceed analyst expectations Second quarter 2024 results: Revenue: €860.7m (up 3.4% from 2Q 2023). Net income: €23.9m (down 75% from 2Q 2023). Profit margin: 2.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.8%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Reported Earnings • Apr 18
First quarter 2024 earnings: Revenues miss analyst expectations First quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 5.4%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Upcoming Dividend • Mar 26
Upcoming dividend of €0.74 per share Eligible shareholders must have bought the stock before 02 April 2024. Payment date: 04 April 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (0.6%). Reported Earnings • Feb 18
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: €3.00 (down from €9.91 in FY 2022). Revenue: €3.40b (down 19% from FY 2022). Net income: €205.2m (down 70% from FY 2022). Profit margin: 6.0% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Declared Dividend • Feb 12
Dividend of €0.74 announced Shareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 15%. Cash payout ratio: 46%. Announcement • Feb 03
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024 Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €353, the stock trades at a forward P/E ratio of 79x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €335 per share. Announcement • Jan 18
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024 Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €253, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €238 per share. Price Target Changed • Oct 23
Price target decreased by 8.9% to €330 Down from €362, the current price target is an average from 15 analysts. New target price is 37% above last closing price of €240. Stock is down 29% over the past year. The company is forecast to post earnings per share of €3.98 for next year compared to €9.91 last year. Reported Earnings • Oct 20
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €263, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €259 per share. Announcement • Oct 13
Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023 SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development. Reported Earnings • Jul 26
Second quarter 2023 earnings: Revenues miss analyst expectations Second quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 4.8%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €359, the stock trades at a forward P/E ratio of 64x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €226 per share. Price Target Changed • Jul 05
Price target decreased by 9.6% to €367 Down from €406, the current price target is an average from 13 analysts. New target price is 13% above last closing price of €324. Stock is down 11% over the past year. The company is forecast to post earnings per share of €5.84 for next year compared to €9.91 last year. Price Target Changed • Jun 20
Price target decreased by 8.6% to €395 Down from €432, the current price target is an average from 13 analysts. New target price is 32% above last closing price of €300. Stock is down 2.2% over the past year. The company is forecast to post earnings per share of €6.80 for next year compared to €9.91 last year. New Risk • Jun 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (90% net debt to equity). Share price has been volatile over the past 3 months (7.1% average weekly change). Reported Earnings • Apr 23
First quarter 2023 earnings: Revenues miss analyst expectations First quarter 2023 results: Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 7.6%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Upcoming Dividend • Mar 23
Upcoming dividend of €1.44 per share at 0.4% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (0.7%). Reported Earnings • Feb 20
Full year 2022 earnings released Full year 2022 results: Revenue: €4.17b (up 21% from FY 2021). Net income: €678.1m (up 113% from FY 2021). Profit margin: 16% (up from 9.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Announcement • Jan 27
Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023 Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth. Announcement • Jan 04
Sartorius Announces Management Changes for Sartorius North America Sartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 17% share price gain to €393, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 35x in the Life Sciences industry in Europe. Total returns to shareholders of 121% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €199 per share. Price Target Changed • Oct 24
Price target decreased to €441 Down from €483, the current price target is an average from 14 analysts. New target price is 34% above last closing price of €328. Stock is down 43% over the past year. The company is forecast to post earnings per share of €8.91 for next year compared to €4.66 last year. Announcement • Oct 20
Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023 Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023 Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment improved over the past week After last week's 17% share price gain to €403, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 34x in the Life Sciences industry in Europe. Total returns to shareholders of 147% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €247 per share.